--- a
+++ b/matching/trials/NCT00143195.xml
@@ -0,0 +1,231 @@
+<?xml version="1.0" encoding="UTF-8"?>
+<clinical_study rank="189601">
+  <!-- This xml conforms to an XML Schema at:
+    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
+ and an XML DTD at:
+    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
+  <required_header>
+    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
+    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
+    <url>https://clinicaltrials.gov/show/NCT00143195</url>
+  </required_header>
+  <id_info>
+    <org_study_id>A0531076</org_study_id>
+    <nct_id>NCT00143195</nct_id>
+  </id_info>
+  <brief_title>Amlodipine vs Nitrates Study in Patients With Chronic Stable Angina</brief_title>
+  <acronym>ANISSA</acronym>
+  <official_title>Open Label Study Comparing Amlodipine vs Long-Acting Nitrates in Patients With Chronic Stable Angina.</official_title>
+  <sponsors>
+    <lead_sponsor>
+      <agency>Pfizer</agency>
+      <agency_class>Industry</agency_class>
+    </lead_sponsor>
+  </sponsors>
+  <source>Pfizer</source>
+  <oversight_info>
+    <authority>Greece: National Organization of Medicines</authority>
+  </oversight_info>
+  <brief_summary>
+    <textblock>
+      The objective of study is to compare the anti-ischemic efficacy and safety profiles of once
+      daily amlodipine or isosorbide-5-mononitrate in the treatment of stable asymptomatic and
+      symptomatic myocardial ischemia
+    </textblock>
+  </brief_summary>
+  <overall_status>Completed</overall_status>
+  <start_date>April 2001</start_date>
+  <completion_date>January 2005</completion_date>
+  <phase>Phase 4</phase>
+  <study_type>Interventional</study_type>
+  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
+  <primary_outcome>
+    <measure>Evaluate the time to 1mm ST depression</measure>
+  </primary_outcome>
+  <secondary_outcome>
+    <measure>The number of patients experiencing angina attacks The frequency of hospitalizations due to angina attacks Time to onset of 1mm ST segment depression Total external workload performed Safety</measure>
+  </secondary_outcome>
+  <enrollment>200</enrollment>
+  <condition>Myocardial Ischemia</condition>
+  <intervention>
+    <intervention_type>Drug</intervention_type>
+    <intervention_name>Amlodipine</intervention_name>
+  </intervention>
+  <intervention>
+    <intervention_type>Drug</intervention_type>
+    <intervention_name>iso- 5 - mononitrate</intervention_name>
+  </intervention>
+  <intervention>
+    <intervention_type>Procedure</intervention_type>
+    <intervention_name>Blood tests</intervention_name>
+  </intervention>
+  <intervention>
+    <intervention_type>Procedure</intervention_type>
+    <intervention_name>Exercise Stress Test</intervention_name>
+  </intervention>
+  <eligibility>
+    <criteria>
+      <textblock>
+        Inclusion Criteria:
+
+          -  Outpatients &gt; =18 years of age with diagnosed clinically stable angina pectoris
+
+        Exclusion Criteria:
+
+          -  Patients with congestive heart failure, clinically significant cardiovascular
+             disease, standing systolic blood pressure of less than 100mmHg, concomitant
+             anti-anginal therapies similar to sublingual NTG
+      </textblock>
+    </criteria>
+    <gender>Both</gender>
+    <minimum_age>18 Years</minimum_age>
+    <maximum_age>N/A</maximum_age>
+    <healthy_volunteers>No</healthy_volunteers>
+  </eligibility>
+  <overall_official>
+    <last_name>Pfizer CT.gov Call Center</last_name>
+    <role>Study Director</role>
+    <affiliation>Pfizer</affiliation>
+  </overall_official>
+  <location>
+    <facility>
+      <name>Pfizer Investigational Site</name>
+      <address>
+        <city>Athens</city>
+        <state>Attika</state>
+        <zip>11527</zip>
+        <country>Greece</country>
+      </address>
+    </facility>
+  </location>
+  <location>
+    <facility>
+      <name>Pfizer Investigational Site</name>
+      <address>
+        <city>Athens</city>
+        <country>Greece</country>
+      </address>
+    </facility>
+  </location>
+  <location>
+    <facility>
+      <name>Pfizer Investigational Site</name>
+      <address>
+        <city>Athens</city>
+        <zip>123 51</zip>
+        <country>Greece</country>
+      </address>
+    </facility>
+  </location>
+  <location>
+    <facility>
+      <name>Pfizer Investigational Site</name>
+      <address>
+        <city>Holargos/Athens</city>
+        <zip>11525</zip>
+        <country>Greece</country>
+      </address>
+    </facility>
+  </location>
+  <location>
+    <facility>
+      <name>Pfizer Investigational Site</name>
+      <address>
+        <city>Loannina</city>
+        <zip>45500</zip>
+        <country>Greece</country>
+      </address>
+    </facility>
+  </location>
+  <location>
+    <facility>
+      <name>Pfizer Investigational Site</name>
+      <address>
+        <city>N. Ionia</city>
+        <zip>143 88</zip>
+        <country>Greece</country>
+      </address>
+    </facility>
+  </location>
+  <location>
+    <facility>
+      <name>Pfizer Investigational Site</name>
+      <address>
+        <city>Patra</city>
+        <zip>26335</zip>
+        <country>Greece</country>
+      </address>
+    </facility>
+  </location>
+  <location>
+    <facility>
+      <name>Pfizer Investigational Site</name>
+      <address>
+        <city>Rio, Patra</city>
+        <zip>26499</zip>
+        <country>Greece</country>
+      </address>
+    </facility>
+  </location>
+  <location>
+    <facility>
+      <name>Pfizer Investigational Site</name>
+      <address>
+        <city>Thessaloniki</city>
+        <zip>546 36</zip>
+        <country>Greece</country>
+      </address>
+    </facility>
+  </location>
+  <location>
+    <facility>
+      <name>Pfizer Investigational Site</name>
+      <address>
+        <city>Thessaloniki</city>
+        <zip>54639</zip>
+        <country>Greece</country>
+      </address>
+    </facility>
+  </location>
+  <location>
+    <facility>
+      <name>Pfizer Investigational Site</name>
+      <address>
+        <city>Voula/Athens</city>
+        <country>Greece</country>
+      </address>
+    </facility>
+  </location>
+  <location>
+    <facility>
+      <name>Pfizer Investigational Site</name>
+      <address>
+        <city>Zakynthos</city>
+        <zip>29100</zip>
+        <country>Greece</country>
+      </address>
+    </facility>
+  </location>
+  <location_countries>
+    <country>Greece</country>
+  </location_countries>
+  <link>
+    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0531076&amp;StudyName=Amlodipine+vs+NItrates+Study+in+Patients+with+Chronic+Stable++Angina+%28ANISSA%29</url>
+    <description>To obtain contact information for a study center near you, click here.</description>
+  </link>
+  <verification_date>April 2007</verification_date>
+  <lastchanged_date>April 17, 2007</lastchanged_date>
+  <firstreceived_date>August 31, 2005</firstreceived_date>
+  <has_expanded_access>No</has_expanded_access>
+  <condition_browse>
+    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
+    <mesh_term>Angina, Stable</mesh_term>
+    <mesh_term>Coronary Artery Disease</mesh_term>
+    <mesh_term>Myocardial Ischemia</mesh_term>
+  </condition_browse>
+  <intervention_browse>
+    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
+    <mesh_term>Amlodipine</mesh_term>
+  </intervention_browse>
+  <!-- Results have not yet been posted for this study                                -->
+</clinical_study>